Published in J Immunol on September 15, 2007
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood (2012) 1.81
Bcl-2 allows effector and memory CD8+ T cells to tolerate higher expression of Bim. J Immunol (2011) 1.26
Helios marks strongly autoreactive CD4+ T cells in two major waves of thymic deletion distinguished by induction of PD-1 or NF-κB. J Exp Med (2013) 1.26
Genetic control of programmed cell death during animal development. Annu Rev Genet (2009) 1.24
Contracting the 'mus cells'--does down-sizing suit us for diving into the memory pool? Immunol Rev (2010) 1.11
The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens. Immunity (2012) 1.08
Protecting and rescuing the effectors: roles of differentiation and survival in the control of memory T cell development. Front Immunol (2013) 1.08
Bcl-2-regulated cell death signalling in the prevention of autoimmunity. Cell Death Dis (2010) 1.04
Proapoptotic protein Bim is differentially required during thymic clonal deletion to ubiquitous versus tissue-restricted antigens. Proc Natl Acad Sci U S A (2012) 1.03
Modulation of the Bcl-2 family blocks sepsis-induced depletion of dendritic cells and macrophages. Shock (2009) 1.00
miR-148a is upregulated by Twist1 and T-bet and promotes Th1-cell survival by regulating the proapoptotic gene Bim. Eur J Immunol (2015) 0.98
Bim dictates naive CD4 T cell lifespan and the development of age-associated functional defects. J Immunol (2010) 0.98
Alternative splicing of Bim and Erk-mediated Bim(EL) phosphorylation are dispensable for hematopoietic homeostasis in vivo. Cell Death Differ (2012) 0.97
IL-15 Fosters Age-Driven Regulatory T Cell Accrual in the Face of Declining IL-2 Levels. Front Immunol (2013) 0.96
BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. Br J Cancer (2010) 0.91
Intrinsic role of FoxO3a in the development of CD8+ T cell memory. J Immunol (2012) 0.90
Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment. Neoplasia (2013) 0.88
Examination of a second node of translational control in the unfolded protein response. J Cell Sci (2013) 0.83
Elevated Mcl-1 inhibits thymocyte apoptosis and alters thymic selection. Cell Death Differ (2012) 0.78
A novel method for long term bone marrow culture and genetic modification of murine neutrophils via retroviral transduction. J Immunol Methods (2008) 0.78
Dying to protect: cell death and the control of T-cell homeostasis. Immunol Rev (2017) 0.75
Non-Hematopoietic and Hematopoietic SIRPα Signaling Differently Regulates Murine B Cell Maturation in Bone Marrow and Spleen. PLoS One (2015) 0.75
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Seroepidemiology of human polyomaviruses. PLoS Pathog (2009) 4.62
Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity (2002) 4.61
Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med (2014) 3.96
Multigait soft robot. Proc Natl Acad Sci U S A (2011) 3.57
How the T cell repertoire becomes peptide and MHC specific. Cell (2005) 3.39
The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity (2003) 3.19
An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood (2004) 3.19
Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol (2007) 3.19
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol (2004) 2.81
Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol (2010) 2.80
T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol (2001) 2.80
Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol (2008) 2.79
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 2.62
Microsurgical keyhole approach for middle fossa arachnoid cyst fenestration. Neurosurgery (2003) 2.58
Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide. Nat Immunol (2006) 2.57
Promotion of B cell immune responses via an alum-induced myeloid cell population. Science (2004) 2.47
Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol (2009) 2.47
CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci U S A (2002) 2.44
Germline-encoded amino acids in the alphabeta T-cell receptor control thymic selection. Nature (2009) 2.43
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood (2008) 2.33
Effect of vessel size on creation of hepatic radiofrequency lesions in pigs: assessment of the "heat sink" effect. AJR Am J Roentgenol (2002) 2.31
Crossreactive T Cells spotlight the germline rules for alphabeta T cell-receptor interactions with MHC molecules. Immunity (2008) 2.31
Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem (2004) 2.30
T cell allorecognition via molecular mimicry. Immunity (2009) 2.25
Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c⁺ B-cell population is important for the development of autoimmunity. Blood (2011) 2.20
Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol (2003) 2.09
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol (2013) 2.01
How do adjuvants work? Important considerations for new generation adjuvants. Immunity (2007) 2.01
Bim mediates apoptosis of CD127(lo) effector T cells and limits T cell memory. Eur J Immunol (2006) 1.95
A molecular basis for NKT cell recognition of CD1d-self-antigen. Immunity (2011) 1.94
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol (2012) 1.94
Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci U S A (2010) 1.87
Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol (2002) 1.85
T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. Immunity (2009) 1.85
Function and regulation of SPLUNC1 protein in Mycoplasma infection and allergic inflammation. J Immunol (2007) 1.85
A single T cell receptor bound to major histocompatibility complex class I and class II glycoproteins reveals switchable TCR conformers. Immunity (2011) 1.84
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer (2008) 1.82
Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol (2005) 1.77
Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. Proc Natl Acad Sci U S A (2004) 1.72
Ndfip1 protein promotes the function of itch ubiquitin ligase to prevent T cell activation and T helper 2 cell-mediated inflammation. Immunity (2006) 1.71
Life-cycle greenhouse gas emissions of shale gas, natural gas, coal, and petroleum. Environ Sci Technol (2011) 1.70
Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol (2003) 1.69
Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci U S A (2011) 1.68
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood (2009) 1.61
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell (2006) 1.58
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood (2012) 1.58
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood (2009) 1.58
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol (2009) 1.57
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem (2010) 1.55
IgG autoantibodies against deposited C3 inhibit macrophage-mediated apoptotic cell engulfment in systemic autoimmunity. J Immunol (2011) 1.54
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol (2013) 1.52
Percutaneous mechanical and pharmacomechanical thrombolysis for occlusive deep vein thrombosis of the proximal limb in adolescent subjects: findings from an institution-based prospective inception cohort study of pediatric venous thromboembolism. J Vasc Interv Radiol (2011) 1.51
HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. EMBO J (2002) 1.50
Apoptosis and the homeostatic control of immune responses. Curr Opin Immunol (2007) 1.49
Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol (2012) 1.47
Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc Natl Acad Sci U S A (2010) 1.47
CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc Natl Acad Sci U S A (2006) 1.46
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell (2007) 1.45
Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Dig Dis Sci (2010) 1.44
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol (2014) 1.43
Memory CD4 T cells that express CXCR5 provide accelerated help to B cells. J Immunol (2011) 1.43
Transforming the endocrine consult: asynchronous provider consultations. Endocr Pract (2015) 1.41
Mimotopes for alloreactive and conventional T cells in a peptide-MHC display library. PLoS Biol (2004) 1.40
Interaction of JMJD6 with single-stranded RNA. Proc Natl Acad Sci U S A (2010) 1.37
T cell apoptosis and reactive oxygen species. J Clin Invest (2003) 1.35
Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands. Immunol Rev (2006) 1.33
Homeostatically proliferating CD4 T cells are involved in the pathogenesis of an Omenn syndrome murine model. J Clin Invest (2007) 1.32
Adipose is a conserved dosage-sensitive antiobesity gene. Cell Metab (2007) 1.31
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant (2009) 1.31